Navigation Links
terna Zentaris Discloses First In Vitro Data for its PI3K,,,Inhibitors at the AACR Annual Meeting in Los Angeles

Second generation pyridopyrazine-urea derivative compound series show highly selective PI3K-inhibition which could be valuable for cancer treatment

QUBEC CITY, Canada, April 16, 2007 terna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global, pure play biopharmaceutical company focused on endocrine therapy and oncology, today presented an abstract outlining first in vitro data on its pyridopyrazine derivatives with high selectivity for PI3K inhibition, at the American Association for Cancer Research (AACR) Annual Meeting being held this week at the Los Angeles Convention Center in Los Angeles, California.

Results

The poster #2379 entitled, New Generation of Anilino-Substituted Pyridopyrazine-Urea Derivatives Show Highly Selective PI3K-Inhibition, reviewed for the first time, results for a preclinical development program on a new generation of pyridopyrazine derivatives which clearly indicate that these drug candidates selectively inhibit PI3K.

Furthermore, an optimization process of our already known aryl-pyridopyrazine series led to the identification of a new lead compound in this series. A medicinal chemistry program was then initiated which resulted in the synthesis of new anilino-substituted pyridopyrazines. Out of this second generation series, several derivatives also with highly-selective PI3K inhibition as well as improved cellular efficacy and better drug-like properties, were identified.

Conclusions






Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Childrens Hospital and Stanford
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  In an unprecedented effort to curb the ... ambulances and other transport vehicles, an advanced and portable UV germicidal ... for the first time. In order to prevent ... deadly pathogens, West Palm Beach Fire Rescue ...
(Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
(Date:4/17/2014)... The presence of chronic inflammation in benign ... prostate cancer, and this association was found even ... according to a study published in Cancer ... the American Association for Cancer Research. , An ... participants of the placebo arm of the Prostate ...
(Date:4/17/2014)... to a study published today in PLOS Pathogens ... where malaria is common can mount an immune response ... to avoid repeated bouts of high fever and illness ... their bloodstream. The findings may help researchers develop future ... the malaria parasite. , Each year, approximately 200 million ...
(Date:4/17/2014)... Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, was ... April issue of Nature Reviews Microbiology , ... Dr. McCullers, a world-renowned infectious disease specialist, and ... University of Tennessee Health Science Center, analyzed the ... 1957 and 1968 pandemics, as well as more ...
(Date:4/17/2014)... The cause of neuronal death in Parkinson,s disease is ... may be mistaken for foreign invaders and killed by ... autoimmune diseases like type I diabetes, celiac disease, and ... published April 16, 2014, in Nature Communications . ... in Parkinson,s disease; but if true, it could lead ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2
... ALTO, Calif., April 29 Varian Medical Systems (NYSE: ... continuing operations of $0.64 per diluted share in the ... from continuing operations of $0.57 per diluted share in ... instruments operation, net earnings per diluted share in the ...
... Varian, Inc. (NasdaqGS: VARI) today reported second quarter fiscal ... 17.2% from the second quarter of fiscal year 2008.Non-GAAP ... of 2009 were $0.55 (including $0.05 of share-based compensation ... $0.07 of share-based compensation expense) in the second quarter ...
... juice could slow prostate cancer , , WEDNESDAY, April 29 ... a citrus flavor, might help ward off painful calcium ... citrate, which is known to inhibit calcium formation, according ... be presented Sunday at the American Urological Association annual ...
... years, report warns , , WEDNESDAY, April 29 (HealthDay News) -- ... of new cancers over the next two decades, driven by ... new report predicts. , Rates of new cancer diagnosis ... generally and by 67 percent among people aged 65 or ...
... INDIANAPOLIS , April 29 /PRNewswire/ ... a good start. WellPoint is pleased that the ... underlying quality and cost issues within our health care ... programs and services private plans have pioneered. We also ...
... Nancy Pelosi spoke on the House floor this morning in strong ... The resolution passed the House by a vote of 233 to ... today. It does not require the signature of the President. Below ... indeed an honor to call Mr. Spratt a colleague. We say ...
Cached Medicine News:Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 2Health News:Varian, Inc. Reports Second Quarter 2009 Results 3Health News:Varian, Inc. Reports Second Quarter 2009 Results 4Health News:Varian, Inc. Reports Second Quarter 2009 Results 5Health News:Varian, Inc. Reports Second Quarter 2009 Results 6Health News:Varian, Inc. Reports Second Quarter 2009 Results 7Health News:Varian, Inc. Reports Second Quarter 2009 Results 8Health News:Varian, Inc. Reports Second Quarter 2009 Results 9Health News:Varian, Inc. Reports Second Quarter 2009 Results 10Health News:Varian, Inc. Reports Second Quarter 2009 Results 11Health News:Varian, Inc. Reports Second Quarter 2009 Results 12Health News:Varian, Inc. Reports Second Quarter 2009 Results 13Health News:Varian, Inc. Reports Second Quarter 2009 Results 14Health News:Varian, Inc. Reports Second Quarter 2009 Results 15Health News:Varian, Inc. Reports Second Quarter 2009 Results 16Health News:Varian, Inc. Reports Second Quarter 2009 Results 17Health News:Varian, Inc. Reports Second Quarter 2009 Results 18Health News:Varian, Inc. Reports Second Quarter 2009 Results 19Health News:Varian, Inc. Reports Second Quarter 2009 Results 20Health News:Varian, Inc. Reports Second Quarter 2009 Results 21Health News:Varian, Inc. Reports Second Quarter 2009 Results 22Health News:Varian, Inc. Reports Second Quarter 2009 Results 23Health News:Some Diet Sodas May Ward Off Kidney Stones 2Health News:Some Diet Sodas May Ward Off Kidney Stones 3Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 2Health News:Minorities to Bear Brunt of Rise in U.S. Cancer Cases 3Health News:Pelosi: Budget is a Blueprint for the Future 2
Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
... Cordis biopsy forceps are designed for endomyocardial biopsies. ... consist of a 3-pull ring handle, stainless steel ... thumb ring rotates to accommodate any position. ,A ... closed. The jaws are opened by moving the ...
4-Strand Basket Retriever was developed to facilitate recovery of foreign objects from within the neuro, peripheral, and cardiovasculature, the In-Time Retrieval Device features an integrated corewir...
... non-invasive, virtually pain-free alternative to conventional open ... indications. With Leksell Gamma Knife C the ... improves the ability to mould the radiation ... allows a more selective irradiation and thus ...
Medicine Products: